Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 526.95 Billion | 478.88 Billion | 354.17 Billion | 308.5 Billion | 317.82 Billion | 286.65 Billion |
| Cost of Revenue | 272.71 Billion | 240.94 Billion | 177.7 Billion | 142.56 Billion | 137.67 Billion | 121.16 Billion |
| Gross Profit | 254.23 Billion | 237.94 Billion | 176.46 Billion | 165.93 Billion | 180.15 Billion | 165.48 Billion |
| Operating Expenses | 221.99 Billion | 194.93 Billion | 157.04 Billion | 141.83 Billion | 145.04 Billion | 134.74 Billion |
| Selling, General and Administrative Expenses | 203.79 Billion | 99.61 Billion | 78.52 Billion | 65.45 Billion | 68.39 Billion | 64.52 Billion |
| Research and Development Expenses | 18.2 Billion | 19.47 Billion | 24.56 Billion | 13.47 Billion | 10.24 Billion | 9.27 Billion |
| Other Expenses | - | 95.32 Billion | 78.51 Billion | 62.9 Billion | 66.41 Billion | 1.28 Billion |
| Cost and Expenses | 494.71 Billion | 435.87 Billion | 334.75 Billion | 284.4 Billion | 282.72 Billion | 255.9 Billion |
| Operating Income | 32.23 Billion | 43 Billion | 19.42 Billion | 24.09 Billion | 35.1 Billion | 30.74 Billion |
| Interest Expense | 4.61 Billion | 3.68 Billion | 2.07 Billion | 1.18 Billion | 268.57 Million | 89.41 Million |
| Income Tax Expense | 2.36 Billion | 8.06 Billion | 10.52 Billion | 6.44 Billion | 8.49 Billion | 7.92 Billion |
| Earnings before Tax | 25.83 Billion | 38.72 Billion | 17.13 Billion | 23.64 Billion | 35.37 Billion | 31.2 Billion |
| Net Income | 23.91 Billion | 31.94 Billion | 6.98 Billion | 17.64 Billion | 27.28 Billion | 23.74 Billion |
| Earnings Per Share Basic | 1139.91 | 1509.75 | 329.36 | 826.31 | 1265.08 | 1100.64 |
| Earnings Per Share Diluted | 1104.19 | 1478.37 | 329.36 | 826.31 | 1265.08 | 1068.54 |
| Weighted Average Shares Outstanding | 20.98 Million | 21.15 Million | 21.21 Million | 21.34 Million | 21.57 Million | 21.57 Million |
| Weighted Average Shares Outstanding (Diluted) | 21.66 Million | 21.87 Million | 21.21 Million | 21.34 Million | 21.57 Million | 22.22 Million |
| Gross Margin | 0.48 | 0.50 | 0.50 | 0.54 | 0.57 | 0.58 |
| EBIT Margin | 0.09 | 0.14 | 0.11 | 0.13 | 0.15 | 0.15 |
| Profit Margin | 0.05 | 0.07 | 0.02 | 0.06 | 0.09 | 0.08 |
| EBITDA | 49.79 Billion | 62.27 Billion | 37.1 Billion | 39.65 Billion | 47.44 Billion | 40.98 Billion |
| Earnings Before Tax Margin | 0.06 | 0.09 | 0.05 | 0.08 | 0.11 | 0.11 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 137.95 Billion | 158.3 Billion | 140.85 Billion | 526.95 Billion | 128.97 Billion | 133.03 Billion |
| Cost of Revenue | 76.43 Billion | 78.76 Billion | 71.44 Billion | 272.71 Billion | 68.97 Billion | 67.53 Billion |
| Gross Profit | 61.52 Billion | 79.53 Billion | 69.41 Billion | 254.23 Billion | 60 Billion | 65.49 Billion |
| Operating Expenses | 63.61 Billion | 64.17 Billion | 62.95 Billion | 221.99 Billion | -53.26 Billion | -55.43 Billion |
| Selling, General and Administrative Expenses | 57.71 Billion | 59.24 Billion | 57.64 Billion | - | 53.26 Billion | 55.43 Billion |
| Research and Development Expenses | 5.9 Billion | 4.92 Billion | 5.31 Billion | - | 4.46 Billion | 4.45 Billion |
| Other Expenses | -165 Thousand | -186 Thousand | 503.34 Million | 1.11 Billion | -106.53 Billion | -110.87 Billion |
| Cost and Expenses | 140.04 Billion | 142.93 Billion | 134.4 Billion | 494.71 Billion | 68.97 Billion | 67.53 Billion |
| Operating Income | -2.08 Billion | 15.36 Billion | 6.45 Billion | 32.23 Billion | 6.74 Billion | 10.06 Billion |
| Interest Expense | 2.33 Billion | 2.47 Billion | 1.17 Billion | 4.61 Billion | 1.15 Billion | 1.17 Billion |
| Income Tax Expense | -768.33 Million | 2.63 Billion | 1.66 Billion | 2.36 Billion | 492.33 Million | 1.57 Billion |
| Earnings before Tax | -3.23 Billion | 11.73 Billion | 2.21 Billion | 25.32 Billion | 5.82 Billion | 9.57 Billion |
| Net Income | -765.4 Million | 9.24 Billion | 749.45 Million | 23.91 Billion | 5.45 Billion | 8.07 Billion |
| Earnings Per Share Basic | -36.11 | 436.34 | 35.36 | - | 260.15 | 385.30 |
| Earnings Per Share Diluted | -36.11 | 436.34 | 33.20 | - | 251.87 | 375.92 |
| Weighted Average Shares Outstanding | 21.19 Million | 21.19 Million | 21.19 Million | 20.98 Million | 20.97 Million | 20.97 Million |
| Weighted Average Shares Outstanding (Diluted) | 21.19 Million | 21.19 Million | 22.57 Million | 21.66 Million | 21.66 Million | 21.62 Million |
| Gross Margin | 0.45 | 0.50 | 0.49 | 0.48 | 0.47 | 0.49 |
| EBIT Margin | 0.02 | 0.12 | 0.09 | - | 0.47 | 0.49 |
| Profit Margin | -0.01 | 0.06 | 0.01 | 0.05 | 0.04 | 0.06 |
| EBITDA | 2.86 Billion | 19.49 Billion | 12.12 Billion | - | 60 Billion | 65.49 Billion |
| Earnings Before Tax Margin | -0.02 | 0.10 | 0.05 | 0.06 | 0.05 | 0.08 |
HTLFP
300578
SBO
PHYTO
DNN
SGMD